Stacy Fletcher

Looking forward to conversations around therapies and technology progressing with improved investor sentiment, albeit with caution! Investing? How commercially viable is the science? What are the product development/CMC and regulatory/clinical risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! Let’s connect and discuss how Boyds can help! #REAIBoston2024 #BiotechweekBoston

17

Great opportunity in NYC

21

#ICYMI our Chief Executive Officer Jeb Keiper talked with Endpoints News about HPK1, a differentiated next-generation #immunotherapy target for advanced solid tumors. Read the article here: https://lnkd.in/e-KAkZ4z

99

1 Comment

Planning to launch a new product in the BioPharma industry? Let Boston BioPharma Consultants guide you through the process. Our expert advisors specialize in new product planning, helping companies navigate regulatory requirements, market dynamics, and competition. Trust us to turn your vision into a successful reality. Contact us today! #BiotechPharma #Biotech #pharmaceutical #pharma #healthcare #medicine #BostonBioPharmaConsultants #marketing

2